{"gene":"GBA1","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2008,"finding":"GBA1 encodes glucocerebrosidase, a lysosomal enzyme that catalyzes the hydrolysis of the glycolipid glucocerebroside to ceramide and glucose; loss-of-function mutations cause lysosomal storage of glucocerebroside in reticuloendothelial cells leading to Gaucher disease. Nearly 300 unique mutations spanning the gene have been characterized, including missense, nonsense, frameshift, splice-junction mutations, and complex alleles from recombination with the downstream pseudogene GBAP1.","method":"Mutation spectrum review with structural/functional annotation of ~300 GBA variants; recombination events with pseudogene characterized","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic function established by decades of biochemical work; comprehensive mutation-function analysis replicated across many labs","pmids":["18338393"],"is_preprint":false},{"year":2017,"finding":"The N370S GBA1 mutation causes ER retention of β-glucocerebrosidase-1 protein, preventing its trafficking to the lysosome, activating ER stress and the unfolded protein response, triggering Golgi fragmentation, impairing autophagy, and causing lysosomal dysfunction with cholesterol accumulation. This results in mitochondrial damage and increased cell death in patient-derived fibroblasts.","method":"Western blot, immunofluorescence, LysoTracker, Filipin staining (cholesterol), electron microscopy, flow cytometry (apoptosis, ROS, mitochondrial membrane potential) in PD patient-derived N370S/WT fibroblasts","journal":"Movement disorders : official journal of the Movement Disorder Society","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in single lab using patient-derived cells; no independent replication cited","pmids":["28779532"],"is_preprint":false},{"year":2018,"finding":"The L444P heterozygous GBA1 mutation triggers mitochondrial dysfunction by inhibiting two steps critical for mitophagy: mitochondrial priming and autophagy induction. Overexpression of L444P GBA impeded mitochondrial priming and autophagy induction even when endogenous lysosomal GBA activity was intact, whereas genetic depletion of GBA inhibited lysosomal clearance of autophagic cargo, suggesting dual mechanisms.","method":"GbaL444P/WT knockin mice, SH-SY5Y neuroblastoma cells with L444P GBA overexpression, GBA genetic depletion, mitochondrial markers (MitoTracker, TIMM23, TOMM20), LC3B lipidation assay, ROS measurements, postmortem PD brain tissue analysis","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (KI mice, cell overexpression, genetic KD, human tissue), single lab","pmids":["30160596"],"is_preprint":false},{"year":2018,"finding":"L444P GBA heterozygous mutation reduces GBA protein levels and enzymatic activity with concomitant α-synuclein accumulation in the midbrain. α-synuclein knockout or AAV5-mediated GBA overexpression each rescued MPTP-induced dopaminergic neuron loss and motor deficits, establishing that GBA deficiency-driven α-synuclein accumulation renders dopaminergic neurons more susceptible to mitochondrial toxin MPTP.","method":"GBA+/L444P knockin mice, SNCA-/- mice, AAV5-hGBA injection, MPTP neurotoxin treatment, immunohistochemistry, HPLC for dopamine metabolites, behavioral tests, mitochondrial morphology/functional assays, Western blot","journal":"Molecular neurodegeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue with two independent approaches (KO and OE), single lab","pmids":["29310663"],"is_preprint":false},{"year":2018,"finding":"D409H GBA1 mutation markedly accelerates α-synuclein pathology in A53T α-synuclein transgenic mice: it exacerbates insoluble α-synuclein aggregate formation, glial activation, neuronal degeneration, motor abnormalities, and causes loss of dopaminergic neurons in the substantia nigra. This establishes that GBA1 enzyme activity reduction accelerates synucleinopathy progression.","method":"D409H GBA1 knockin × A53T α-synuclein transgenic double-mutant mice; survival analysis, immunohistochemistry, biochemical fractionation for insoluble α-synuclein, motor behavioral testing","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic interaction model with multiple phenotypic readouts, single lab","pmids":["29703245"],"is_preprint":false},{"year":2021,"finding":"GBA1-mutant (heterozygous) patient-derived neurons exhibit prolonged mitochondria-lysosome contacts due to defective modulation of the untethering protein TBC1D15, which mediates Rab7 GTP hydrolysis required for contact untethering. This dysregulation was caused by decreased GBA1 lysosomal enzyme activity and resulted in disrupted mitochondrial distribution and function; restoring GCase activity with a modulator or overexpressing TBC1D15 rescued these defects.","method":"Patient iPSC-derived midbrain dopaminergic neurons, live-cell imaging of mitochondria-lysosome contacts (soma, axons, dendrites), GCase activity assay, TBC1D15 rescue overexpression, GCase modulator treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — human patient-derived neurons, live imaging, pharmacological and genetic rescue, multiple orthogonal methods in single rigorous study","pmids":["33753743"],"is_preprint":false},{"year":2020,"finding":"GBA1 D409V knockin astrocytes exhibit broad lysosomal morphology and functional deficits and dramatically impaired basal and TLR4-dependent cytokine production. Both lysosomal dysfunction and inflammatory responses were normalized by LRRK2 kinase inhibition, demonstrating functional crosstalk between GBA1 and LRRK2 in astrocytes.","method":"Heterozygous and homozygous D409V GBA1 knockin mouse astrocytes; biochemical and image-based lysosomal assays, cytokine transcriptional and secretory analyses (basal and TLR4-stimulated), LRRK2 kinase inhibitor treatment","journal":"Movement disorders : official journal of the Movement Disorder Society","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockin model, multiple orthogonal readouts, pharmacological rescue, single lab","pmids":["32034799"],"is_preprint":false},{"year":2022,"finding":"L444P GBA1 mutation produces an altered membrane sphingolipid profile in patient fibroblasts—overall elevated sphingolipids with a shift toward shorter-chain ceramide, sphingomyelin, and hexosylceramide—that directly accelerates α-synuclein aggregation kinetics in vitro. Ambroxol treatment restored glucocerebrosidase activity, normalized sphingolipid composition, and reversed the pro-aggregation effect, establishing a mechanistic link between GCase loss-of-function, lipid dyshomeostasis, and α-synuclein aggregation.","method":"Shotgun lipidomics of L444P GBA fibroblasts; recombinant α-synuclein aggregation kinetics assay with lipid extracts; lipidomics of resulting fibrils; ambroxol pharmacological rescue","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of lipid-driven α-synuclein aggregation, lipidomics of fibrils, pharmacological rescue, multiple orthogonal methods in one study","pmids":["35362022"],"is_preprint":false},{"year":2022,"finding":"The E326K GBA variant does not cause significant loss of GCase protein or activity, ER retention, or ER stress (in contrast to L444P), yet still leads to increased insoluble α-synuclein aggregates. Additionally, E326K causes a significant increase in lipid droplet number under basal conditions and following oleic acid loading, indicating a distinct, lipid-dyshomeostasis mechanism for this risk variant.","method":"Homozygous and heterozygous E326K human fibroblasts; E326K and L444P SH-SY5Y overexpression lines; GCase activity/protein assays, ER stress markers, α-synuclein solubility fractionation, lipid droplet staining and quantification with/without oleic acid","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two cell systems (fibroblasts and neuroblastoma lines), multiple orthogonal readouts, single lab","pmids":["36130205"],"is_preprint":false},{"year":2022,"finding":"N370S GBA1 mutation in cholinergic neurons reduces GCase protein and activity and cathepsin D levels, and significantly increases both tau and α-synuclein protein levels. Ambroxol, a GCase chaperone, enhanced GCase activity and reversed tau and α-synuclein accumulation, establishing that GBA1 dysfunction impairs proteostasis of both α-synuclein and tau in cholinergic neurons.","method":"Neural crest stem cell-derived cholinergic neurons from N370S/WT PD patients; GCase activity assay, Western blot for GCase/cathepsin D/tau/α-synuclein, ambroxol treatment rescue","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived neuronal model, pharmacological rescue, multiple protein targets assessed, single lab","pmids":["35179198"],"is_preprint":false},{"year":2024,"finding":"Severe GBA1 mutations (L444P, D409H) increase ER stress and total ubiquitination, impair macroautophagy (L444P blocks autophagosome-lysosome fusion; N370S and D409H reduce autophagosome formation), and trigger accumulation and secretion of oligomeric α-synuclein. Mild mutation N370S specifically impairs chaperone-mediated autophagy (CMA) of monomeric α-synuclein. Thus, mild and severe GBA1 mutations cause α-synuclein accumulation through distinct proteostasis mechanisms.","method":"iPSC-derived dopaminergic neurons with N370S (mild), L444P and D409H (severe) GBA1 mutations; ER stress markers, ubiquitination assays, autophagosome formation/fusion assays, CMA activity, oligomeric α-synuclein ELISA and secretion assays","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — iPSC-derived human neurons, multiple degradation pathway readouts across three mutation variants, single lab","pmids":["38641924"],"is_preprint":false},{"year":2024,"finding":"GBA1 inactivation in oligodendrocytes (Cnp1-cre × loxP-Gba1 exons 9-11 flox) induces lysosomal dysfunction and inhibits myelination in vitro, and causes in vivo demyelination, axonal degeneration, α-synuclein accumulation, astrogliosis, brain lipid dyshomeostasis and functional impairment, establishing that oligodendrocyte GCase activity is required for myelination and prevention of early neurodegenerative features.","method":"Oligodendrocyte-specific Gba1 conditional knockout mice (Cnp1-cre × loxP-Gba1); Oli-neu myelination induction model with CBE inhibitor; immunofluorescence, Western blot, lipidomics, primary oligodendrocyte culture differentiation assays","journal":"Molecular neurodegeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO mouse + in vitro inhibitor model, multiple orthogonal readouts including lipidomics, single lab","pmids":["38454456"],"is_preprint":false},{"year":2019,"finding":"GBA1 encodes glucocerebrosidase, and loss of its activity causes accumulation of its glycolipid substrates glucosylceramide and glucosylsphingosine. GBA mutation promotes mitochondrial accumulation and impaired clearance of depolarized mitochondria in GBA-mutant neurospheres (heterozygous and homozygous), with compensatory upregulation of TFEB and PGC1α mRNA, indicating impaired mitochondrial quality control downstream of GCase deficiency.","method":"3D neurosphere model from neural crest stem cells with heterozygous and homozygous GBA mutations; CCCP-induced mitophagy; mitochondrial content/function markers, ATP levels, TFEB and PGC1α mRNA quantification, macroautophagy flux assay","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3D neuronal model, multiple mitochondrial readouts, comparison of hetero- and homozygous lines, single lab","pmids":["31751314"],"is_preprint":false},{"year":2024,"finding":"An African ancestry-specific noncoding GBA1 risk variant (rs3115534-G) disrupts an intronic branchpoint sequence in intron 8, causing retention of a partial intron 8 in transcripts. This intron-retained isoform is not protein-coding (confirmed by N-terminal antibody staining and proteomics). CRISPR editing of rs3115534 confirmed it drives aberrant splicing. Risk variant carriers show a dose-dependent reduction in glucocerebrosidase activity, establishing that this noncoding variant reduces functional GBA1 protein through a splicing mechanism.","method":"Full-length RNA transcript sequencing in risk variant vs. non-variant carriers; N-terminal GCase antibody immunoblot; proteomics; CRISPR editing of rs3115534; glucocerebrosidase activity assay across genotypes","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — CRISPR functional validation of specific variant, RNA sequencing, proteomics, enzymatic activity, multiple orthogonal methods in one rigorous study","pmids":["39668204"],"is_preprint":false},{"year":2012,"finding":"GBA2 (non-lysosomal β-glucosidase) enzymatic activity accounts for over 85% of total brain GBA activity in wild-type mice, and is significantly elevated in GBA1-deficient mice brains compared to heterozygotes and wild-types. Some Gaucher disease patients also show markedly elevated GBA2 activity in leukocytes, suggesting a compensatory upregulation of GBA2 in response to GBA1 deficiency.","method":"Enzymatic activity assays for GBA1 and GBA2 in brain tissue from wild-type, heterozygous, and GBA1-deficient mice; GBA2 activity assay in leukocytes from 13 Gaucher patients, 10 heterozygotes, and 19 controls","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct enzymatic assays in animal tissues and human patient leukocytes, single lab, no independent replication cited","pmids":["23151684"],"is_preprint":false},{"year":2017,"finding":"GBA1 (Gba1a ortholog) was identified in a signalome-wide RNAi screen as a mediator of autophagic cell death. Knockdown of Gba1a in two independent Drosophila RNAi lines delayed developmental midgut cell death during metamorphosis, establishing that GBA1 is a conserved critical regulator of autophagy levels required for autophagic cell death.","method":"RNAi screen in human lung carcinoma cells (resveratrol-induced autophagic death); two independent Gba1a RNAi lines in Drosophila midgut; morphological analysis of midgut regression during metamorphosis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent RNAi lines in Drosophila, ortholog context, confirmed in screen + in vivo model; single lab","pmids":["28933588"],"is_preprint":false},{"year":2024,"finding":"Downregulation of the transcriptional repressor SATB1 leads to derepression of miR-22-3p, which reduces GBA1 expression and causes glucocerebroside accumulation. This GluCer increase alone is sufficient to impair lysosomal and mitochondrial function, inducing a cellular senescence-like phenotype in dopaminergic neurons. The SATB1–miR-22–GBA1 regulatory axis was dysregulated in PD patients and normal aging.","method":"Human and murine neuronal lines, iPSC-derived dopaminergic neurons, and mice; SATB1 knockdown, miR-22-3p manipulation, GBA expression measurement, GluCer quantification, lysosomal/mitochondrial function assays, senescence markers","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple model systems (cell lines, iPSC neurons, mice), pathway validated step-by-step, single lab","pmids":["38303548"],"is_preprint":false},{"year":2025,"finding":"In iPSC-derived midbrain organoids from GBA1-PD patients, retention of mutant glucocerebrosidase in the ER and elevated glucosylceramide levels are determinants of α-synuclein aggregation into Lewy body-like inclusions with fibrillary structure and seeding activity. Reduction of GCase activity accelerated fibrillary α-synuclein deposition. Ambroxol and GZ667161 (GCase modulators) reduced α-synuclein pathology in this model.","method":"Patient iPSC-derived midbrain organoids; ER retention immunostaining, glucosylceramide quantification, α-synuclein seeding assay (propagation to healthy organoids), ambroxol/GZ667161 pharmacological rescue","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human patient-derived 3D organoid model, seeding assay, pharmacological rescue, multiple readouts, single lab","pmids":["39570889"],"is_preprint":false},{"year":2022,"finding":"PGRN (progranulin, encoded by GRN) is a modifier of GCase (GBA1): PGRN deficiency in Gba9v/9v (D409V homozygous) mice exacerbates Gaucher disease phenotypes, neuroinflammation (microgliosis, astrogliosis), impaired autophagy, and PD-like pathology. A PGRN-derived peptide (ND7) that crosses the blood-brain barrier ameliorated neuropathic Gaucher and PD pathology in Gba1-mutant mice, identifying PGRN as a functional GBA1 pathway modifier.","method":"Grn KO × Gba9v/9v double-mutant mice; neurobehavioral testing, neuropathology, neuroinflammation markers, autophagy assays; ND7 peptide BBB penetration assay, ex vivo patient fibroblast rescue, in vivo rescue in Gba9v/null and PG9V mice","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — double-mutant genetic interaction in vivo + pharmacological rescue, multiple readouts, single lab","pmids":["36574647"],"is_preprint":false},{"year":2024,"finding":"Long-read RNA sequencing in human brain identified currently unannotated GBA1 transcripts, including protein-coding transcripts lacking the known lysosomal targeting domain that account for almost a third of GBA1 transcription, and revealed that >50% of short-read RNA-seq reads from GBA1 also map to the pseudogene GBAP1, indicating previous expression analyses were confounded. This suggests GBA1 has nonlysosomal isoforms translated in the brain.","method":"Long-read RNA sequencing (human brain); single-nucleus RNA sequencing; proteomics to confirm translation of novel isoforms; comparison with short-read RNA-seq","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — long-read sequencing + proteomics translation confirmation, novel finding from single rigorous study; nonlysosomal function of novel isoforms not yet characterized","pmids":["38924406"],"is_preprint":false}],"current_model":"GBA1 encodes lysosomal glucocerebrosidase (GCase), which hydrolyzes glucocerebroside to ceramide and glucose; loss-of-function mutations cause ER retention of misfolded GCase, ER stress/UPR activation, lysosomal dysfunction with glucosylceramide and glucosylsphingosine accumulation, impaired autophagy-lysosomal pathway (affecting macroautophagy, CMA, and mitophagy in variant-specific ways), and downstream α-synuclein and tau accumulation—with α-synuclein aggregation further promoted by GCase-deficiency-driven sphingolipid dyshomeostasis; additionally, GBA1 deficiency dysregulates mitochondria-lysosome contact untethering via TBC1D15/Rab7, disrupts oligodendrocyte myelination, and is regulated upstream by a SATB1–miR-22–GBA1 transcriptional axis, while a noncoding African ancestry risk variant acts by disrupting an intronic branchpoint to impair GBA1 splicing and reduce GCase activity."},"narrative":{"mechanistic_narrative":"GBA1 encodes lysosomal glucocerebrosidase (GCase), which hydrolyzes the glycolipid glucocerebroside to ceramide and glucose; loss-of-function mutations cause lysosomal storage of glucocerebroside and underlie Gaucher disease, with nearly 300 characterized variants including complex alleles arising from recombination with the GBAP1 pseudogene [PMID:18338393]. Pathogenic missense alleles disrupt GCase through variant-specific routes: severe mutations such as N370S and L444P drive ER retention of misfolded enzyme, activating ER stress and the unfolded protein response, fragmenting the Golgi, and impairing autophagy and lysosomal function, with downstream mitochondrial damage and cell death [PMID:28779532, PMID:38641924]. Loss of GCase activity produces accumulation of its substrates glucosylceramide and glucosylsphingosine and a broader sphingolipid dyshomeostasis [PMID:31751314, PMID:35362022], and this lipid imbalance directly accelerates α-synuclein aggregation kinetics in vitro [PMID:35362022]; the milder E326K risk variant promotes insoluble α-synuclein and lipid-droplet accumulation without measurable enzyme loss or ER stress, defining a distinct lipid-centric mechanism [PMID:36130205]. GCase deficiency impairs proteostasis through mutation-specific degradation defects — severe alleles block macroautophagy and CMA differently — leading to accumulation of both α-synuclein and tau, reversible by the GCase chaperone ambroxol [PMID:35179198, PMID:38641924]. In patient-derived midbrain neurons and organoids, reduced GCase drives α-synuclein into Lewy-body-like fibrillar inclusions with seeding activity and accelerates dopaminergic vulnerability, with genetic or pharmacological restoration of GCase or α-synuclein removal providing rescue [PMID:29310663, PMID:39570889]. GCase deficiency also dysregulates mitochondrial quality control, including prolonged mitochondria–lysosome contacts via defective TBC1D15/Rab7-mediated untethering [PMID:33753743, PMID:31751314], impairs oligodendrocyte myelination [PMID:38454456], and engages cell-type-specific crosstalk with LRRK2 in astrocytes and with progranulin as a pathway modifier [PMID:32034799, PMID:36574647]. GBA1 expression is controlled upstream by a SATB1–miR-22 axis [PMID:38303548], and an African-ancestry noncoding variant disrupts an intronic branchpoint to cause intron retention and reduce functional GCase [PMID:39668204].","teleology":[{"year":2008,"claim":"Established the core biochemical identity of GBA1 as lysosomal glucocerebrosidase and catalogued the loss-of-function mutation spectrum that causes Gaucher disease, framing the gene as an enzyme whose mutations span every functional class.","evidence":"Comprehensive mutation-function review with structural annotation of ~300 variants and pseudogene recombination characterization","pmids":["18338393"],"confidence":"High","gaps":["Does not address how individual mutations differ mechanistically beyond enzyme loss","Connection to neurodegeneration not yet established"]},{"year":2017,"claim":"Showed that the severe N370S allele acts not merely by reducing catalysis but by retaining misfolded enzyme in the ER, linking GBA1 mutation to ER stress, UPR, Golgi fragmentation, autophagy impairment, and mitochondrial damage.","evidence":"Multi-modal imaging, cholesterol staining, EM, and flow cytometry in N370S/WT patient fibroblasts","pmids":["28779532"],"confidence":"Medium","gaps":["Single patient-derived cell type","Does not show how ER retention couples to downstream α-synuclein pathology"]},{"year":2018,"claim":"Defined dual mechanisms by which the L444P allele disrupts mitochondrial quality control — impeding mitophagy priming/autophagy induction independently of lysosomal activity while genetic loss blocks autophagic cargo clearance — and demonstrated that GBA-driven α-synuclein accumulation renders dopaminergic neurons vulnerable, rescued by SNCA knockout or GBA overexpression.","evidence":"L444P knockin mice, SH-SY5Y overexpression/depletion, MPTP challenge, SNCA-/- and AAV-GBA rescue, human PD tissue","pmids":["30160596","29310663"],"confidence":"Medium","gaps":["Mechanism of activity-independent mitophagy block not molecularly resolved","Single-lab in vivo models"]},{"year":2018,"claim":"Demonstrated in vivo that reduced GBA1 activity accelerates synucleinopathy progression, establishing a genetic interaction between GBA1 deficiency and α-synuclein toxicity.","evidence":"D409H GBA1 knockin × A53T α-synuclein transgenic double-mutant mice with neuropathological and behavioral readouts","pmids":["29703245"],"confidence":"Medium","gaps":["Does not isolate enzyme loss from misfolding contributions","Mechanism linking GCase loss to aggregation not addressed here"]},{"year":2019,"claim":"Connected substrate accumulation (glucosylceramide, glucosylsphingosine) to impaired clearance of depolarized mitochondria with compensatory TFEB/PGC1α induction, placing mitochondrial quality control downstream of GCase deficiency.","evidence":"3D neurosphere model with hetero/homozygous GBA mutations, CCCP mitophagy, autophagy flux assays","pmids":["31751314"],"confidence":"Medium","gaps":["Compensatory transcriptional response not functionally validated","Single model system"]},{"year":2020,"claim":"Revealed cell-type-specific GBA1 biology in astrocytes and functional crosstalk with LRRK2, showing lysosomal and inflammatory deficits normalized by LRRK2 kinase inhibition.","evidence":"D409V knockin mouse astrocytes, lysosomal assays, TLR4-stimulated cytokine analysis, LRRK2 inhibitor rescue","pmids":["32034799"],"confidence":"Medium","gaps":["Molecular basis of GBA1–LRRK2 crosstalk undefined","Single lab"]},{"year":2021,"claim":"Identified a specific organelle-contact mechanism: GCase deficiency prolongs mitochondria–lysosome contacts through defective TBC1D15-mediated Rab7 GTP hydrolysis, with rescue by GCase modulation or TBC1D15 overexpression.","evidence":"Patient iPSC-derived midbrain dopaminergic neurons, live-cell contact imaging, GCase activity assays, genetic and pharmacological rescue","pmids":["33753743"],"confidence":"High","gaps":["How reduced GCase activity mechanistically impairs TBC1D15 function unresolved"]},{"year":2022,"claim":"Distinguished mechanistically divergent variants — L444P drives sphingolipid remodeling that directly accelerates α-synuclein aggregation in vitro, whereas E326K promotes insoluble α-synuclein and lipid droplets without enzyme loss or ER stress — establishing lipid dyshomeostasis as a unifying yet variant-specific driver, with ambroxol rescue for L444P.","evidence":"Shotgun lipidomics, recombinant α-synuclein aggregation kinetics, fibril lipidomics, E326K/L444P fibroblast and SH-SY5Y lines, ambroxol rescue","pmids":["35362022","36130205"],"confidence":"High","gaps":["Causal lipid species not definitively isolated","E326K lipid-droplet mechanism not linked to aggregation pathway"]},{"year":2022,"claim":"Extended GBA1 proteostasis dysfunction beyond α-synuclein to tau in cholinergic neurons, and identified progranulin (GRN) as a functional GBA1 pathway modifier amenable to peptide-based rescue.","evidence":"N370S patient-derived cholinergic neurons with ambroxol rescue; Grn KO × Gba9v/9v double-mutant mice with ND7 peptide rescue","pmids":["35179198","36574647"],"confidence":"Medium","gaps":["Mechanism linking GCase to tau proteostasis undefined","PGRN–GCase molecular interaction not resolved"]},{"year":2024,"claim":"Resolved that mild versus severe GBA1 mutations cause α-synuclein accumulation through distinct degradation defects — severe alleles block macroautophagy and trigger oligomer secretion, while N370S selectively impairs CMA of monomeric α-synuclein.","evidence":"iPSC-derived dopaminergic neurons across N370S, L444P, D409H variants; autophagosome formation/fusion, CMA, oligomer ELISA and secretion assays","pmids":["38641924"],"confidence":"Medium","gaps":["Single lab","Does not establish which defect dominates in patient brain"]},{"year":2024,"claim":"Expanded GBA1 biology beyond neurons to oligodendrocytes, showing GCase activity is required for myelination and prevention of demyelination, axonal degeneration, and α-synuclein accumulation.","evidence":"Oligodendrocyte-specific Gba1 conditional knockout mice and Oli-neu CBE inhibitor model with lipidomics and differentiation assays","pmids":["38454456"],"confidence":"Medium","gaps":["Lipid species driving myelination defect not pinpointed","Single lab"]},{"year":2024,"claim":"Defined upstream transcriptional control of GBA1 via a SATB1–miR-22 axis and showed glucocerebroside accumulation alone is sufficient to induce a senescence-like phenotype in dopaminergic neurons.","evidence":"Neuronal lines, iPSC-derived dopaminergic neurons and mice; SATB1 knockdown, miR-22 manipulation, GluCer quantification, senescence markers","pmids":["38303548"],"confidence":"Medium","gaps":["Direct miR-22 binding to GBA1 transcript not detailed here","Relevance of senescence to PD progression unestablished"]},{"year":2024,"claim":"Established a noncoding splicing mechanism for an African-ancestry risk variant — rs3115534 disrupts an intron 8 branchpoint causing non-coding intron-retained transcripts and dose-dependent GCase reduction — and revealed unannotated brain GBA1 isoforms lacking the lysosomal targeting domain plus pervasive GBAP1 read confounding.","evidence":"Full-length and long-read RNA sequencing, snRNA-seq, proteomics, CRISPR editing, and GCase activity assays across genotypes in human brain and carriers","pmids":["39668204","38924406"],"confidence":"High","gaps":["Function of nonlysosomal GBA1 isoforms uncharacterized","Whether intron-retained transcript has any cellular role unknown"]},{"year":2025,"claim":"Demonstrated in human midbrain organoids that ER retention of mutant GCase and elevated glucosylceramide are determinants of fibrillar, seeding-competent α-synuclein inclusions, with GCase modulators reducing pathology.","evidence":"GBA1-PD patient iPSC-derived midbrain organoids, ER retention staining, GluCer quantification, α-synuclein seeding/propagation assay, ambroxol/GZ667161 rescue","pmids":["39570889"],"confidence":"Medium","gaps":["Single lab","Relative contributions of ER retention versus substrate accumulation not separated"]},{"year":null,"claim":"It remains unknown what the nonlysosomal, brain-translated GBA1 isoforms lacking the lysosomal targeting domain actually do, and how the diverse variant-specific mechanisms (ER stress, lipid dyshomeostasis, autophagy/CMA defects, organelle-contact dysregulation) are quantitatively integrated to determine neurodegenerative outcome.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No functional assignment for nonlysosomal isoforms","No unified model weighting competing pathogenic mechanisms","Substrate-of-aggregation lipid species not definitively identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,12,14]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,12]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[0,1,5]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,8,17]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[1,10,12,15]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,7,12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,3,4,17]}],"complexes":[],"partners":["TBC1D15","RAB7","LRRK2","GRN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P04062","full_name":"Lysosomal acid glucosylceramidase","aliases":["Acid beta-glucosidase","Alglucerase","Beta-glucocerebrosidase","Beta-GC","Beta-glucosylceramidase 1","Cholesterol glucosyltransferase","SGTase","Cholesteryl-beta-glucosidase","D-glucosyl-N-acylsphingosine glucohydrolase","Glucosylceramidase beta 1","Imiglucerase","Lysosomal cholesterol glycosyltransferase","Lysosomal galactosylceramidase","Lysosomal glycosylceramidase"],"length_aa":536,"mass_kda":59.7,"function":"Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose (PubMed:15916907, PubMed:24211208, PubMed:32144204, PubMed:39395789, PubMed:9201993). Plays a central role in the degradation of complex lipids and the turnover of cellular membranes (PubMed:27378698). Through the production of ceramides, participates in the PKC-activated salvage pathway of ceramide formation (PubMed:19279011). Catalyzes the glucosylation of cholesterol, through a transglucosylation reaction where glucose is transferred from GlcCer to cholesterol (PubMed:24211208, PubMed:26724485, PubMed:32144204). GlcCer containing mono-unsaturated fatty acids (such as beta-D-glucosyl-N-(9Z-octadecenoyl)-sphing-4-enine) are preferred as glucose donors for cholesterol glucosylation when compared with GlcCer containing same chain length of saturated fatty acids (such as beta-D-glucosyl-N-octadecanoyl-sphing-4-enine) (PubMed:24211208). Under specific conditions, may alternatively catalyze the reverse reaction, transferring glucose from cholesteryl 3-beta-D-glucoside to ceramide (Probable) (PubMed:26724485). Can also hydrolyze cholesteryl 3-beta-D-glucoside producing glucose and cholesterol (PubMed:24211208, PubMed:26724485, PubMed:39395789). Catalyzes the hydrolysis of galactosylceramides/GalCers (such as beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine), as well as the transfer of galactose between GalCers and cholesterol in vitro, but with lower activity than with GlcCers (PubMed:32144204). Contrary to GlcCer and GalCer, xylosylceramide/XylCer (such as beta-D-xyosyl-(1<->1')-N-acylsphing-4-enine) is not a good substrate for hydrolysis, however it is a good xylose donor for transxylosylation activity to form cholesteryl 3-beta-D-xyloside (PubMed:33361282). Can also metabolize plant glycosyl phytosterols such as glucosylstigmasterol (PubMed:39395789)","subcellular_location":"Lysosome membrane","url":"https://www.uniprot.org/uniprotkb/P04062/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GBA1","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GBA1","total_profiled":1310},"omim":[{"mim_id":"606463","title":"GLUCOSIDASE, BETA, ACID; GBA","url":"https://www.omim.org/entry/606463"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GBA1"},"hgnc":{"alias_symbol":[],"prev_symbol":["GLUC","GBA"]},"alphafold":{"accession":"P04062","domains":[{"cath_id":"2.60.40.1180","chopping":"75-114_472-533","consensus_level":"high","plddt":97.6878,"start":75,"end":533},{"cath_id":"3.20.20.80","chopping":"119-468","consensus_level":"high","plddt":97.5538,"start":119,"end":468}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P04062","model_url":"https://alphafold.ebi.ac.uk/files/AF-P04062-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P04062-F1-predicted_aligned_error_v6.png","plddt_mean":93.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GBA1","jax_strain_url":"https://www.jax.org/strain/search?query=GBA1"},"sequence":{"accession":"P04062","fasta_url":"https://rest.uniprot.org/uniprotkb/P04062.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P04062/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P04062"}},"corpus_meta":[{"pmid":"18338393","id":"PMC_18338393","title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).","date":"2008","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/18338393","citation_count":508,"is_preprint":false},{"pmid":"23079555","id":"PMC_23079555","title":"The link between the GBA gene and parkinsonism.","date":"2012","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23079555","citation_count":455,"is_preprint":false},{"pmid":"27632223","id":"PMC_27632223","title":"Survival and dementia in GBA-associated Parkinson's disease: The mutation matters.","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27632223","citation_count":323,"is_preprint":false},{"pmid":"25653295","id":"PMC_25653295","title":"Differential effects of severe vs mild GBA mutations on Parkinson disease.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25653295","citation_count":312,"is_preprint":false},{"pmid":"18434642","id":"PMC_18434642","title":"Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.","date":"2008","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18434642","citation_count":306,"is_preprint":false},{"pmid":"31010158","id":"PMC_31010158","title":"GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31010158","citation_count":208,"is_preprint":false},{"pmid":"31755958","id":"PMC_31755958","title":"Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31755958","citation_count":196,"is_preprint":false},{"pmid":"30160596","id":"PMC_30160596","title":"Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations.","date":"2018","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/30160596","citation_count":191,"is_preprint":false},{"pmid":"35455941","id":"PMC_35455941","title":"GBA Variants and Parkinson Disease: Mechanisms and Treatments.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35455941","citation_count":178,"is_preprint":false},{"pmid":"33753743","id":"PMC_33753743","title":"Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33753743","citation_count":152,"is_preprint":false},{"pmid":"32658388","id":"PMC_32658388","title":"GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort.","date":"2020","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/32658388","citation_count":123,"is_preprint":false},{"pmid":"29884970","id":"PMC_29884970","title":"GBA-Associated Parkinson's Disease and Other Synucleinopathies.","date":"2018","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/29884970","citation_count":122,"is_preprint":false},{"pmid":"29310663","id":"PMC_29310663","title":"α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.","date":"2018","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/29310663","citation_count":111,"is_preprint":false},{"pmid":"35106798","id":"PMC_35106798","title":"GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.","date":"2022","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/35106798","citation_count":103,"is_preprint":false},{"pmid":"28779532","id":"PMC_28779532","title":"N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.","date":"2017","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/28779532","citation_count":97,"is_preprint":false},{"pmid":"32034799","id":"PMC_32034799","title":"Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.","date":"2020","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/32034799","citation_count":87,"is_preprint":false},{"pmid":"34984729","id":"PMC_34984729","title":"Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers.","date":"2022","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34984729","citation_count":84,"is_preprint":false},{"pmid":"28890071","id":"PMC_28890071","title":"Serum lipid alterations in GBA-associated Parkinson's disease.","date":"2017","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/28890071","citation_count":80,"is_preprint":false},{"pmid":"29064079","id":"PMC_29064079","title":"Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.","date":"2017","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/29064079","citation_count":74,"is_preprint":false},{"pmid":"35362022","id":"PMC_35362022","title":"Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation.","date":"2022","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35362022","citation_count":68,"is_preprint":false},{"pmid":"33446243","id":"PMC_33446243","title":"Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.","date":"2021","source":"Translational neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/33446243","citation_count":67,"is_preprint":false},{"pmid":"35101134","id":"PMC_35101134","title":"LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.","date":"2022","source":"Translational neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/35101134","citation_count":64,"is_preprint":false},{"pmid":"32853481","id":"PMC_32853481","title":"GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes.","date":"2020","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/32853481","citation_count":63,"is_preprint":false},{"pmid":"34151863","id":"PMC_34151863","title":"Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations.","date":"2021","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/34151863","citation_count":62,"is_preprint":false},{"pmid":"33209983","id":"PMC_33209983","title":"The SPID-GBA study: Sex distribution, Penetrance, Incidence, and Dementia in GBA-PD.","date":"2020","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33209983","citation_count":61,"is_preprint":false},{"pmid":"32618053","id":"PMC_32618053","title":"A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.","date":"2020","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/32618053","citation_count":59,"is_preprint":false},{"pmid":"34248830","id":"PMC_34248830","title":"Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34248830","citation_count":59,"is_preprint":false},{"pmid":"37080432","id":"PMC_37080432","title":"Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.","date":"2023","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37080432","citation_count":51,"is_preprint":false},{"pmid":"32509770","id":"PMC_32509770","title":"Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32509770","citation_count":50,"is_preprint":false},{"pmid":"26743617","id":"PMC_26743617","title":"Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.","date":"2015","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/26743617","citation_count":49,"is_preprint":false},{"pmid":"28727984","id":"PMC_28727984","title":"GBA Analysis in Next-Generation Era: Pitfalls, Challenges, and Possible Solutions.","date":"2017","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/28727984","citation_count":49,"is_preprint":false},{"pmid":"36034282","id":"PMC_36034282","title":"Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36034282","citation_count":43,"is_preprint":false},{"pmid":"31813991","id":"PMC_31813991","title":"LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.","date":"2020","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/31813991","citation_count":43,"is_preprint":false},{"pmid":"31251436","id":"PMC_31251436","title":"Evolution and clustering of prodromal parkinsonian features in GBA1 carriers.","date":"2019","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/31251436","citation_count":43,"is_preprint":false},{"pmid":"35639160","id":"PMC_35639160","title":"GBA-associated PD: chances and obstacles for targeted treatment strategies.","date":"2022","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/35639160","citation_count":42,"is_preprint":false},{"pmid":"30363648","id":"PMC_30363648","title":"A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson's Disease.","date":"2018","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/30363648","citation_count":42,"is_preprint":false},{"pmid":"34741486","id":"PMC_34741486","title":"Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.","date":"2021","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/34741486","citation_count":39,"is_preprint":false},{"pmid":"39267121","id":"PMC_39267121","title":"Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.","date":"2024","source":"Translational neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/39267121","citation_count":38,"is_preprint":false},{"pmid":"37302978","id":"PMC_37302978","title":"GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy.","date":"2023","source":"Journal of movement disorders","url":"https://pubmed.ncbi.nlm.nih.gov/37302978","citation_count":32,"is_preprint":false},{"pmid":"34779914","id":"PMC_34779914","title":"Glucocerebrosidase (GBA) gene variants in a multi-ethnic Asian cohort with Parkinson's disease: mutational spectrum and clinical features.","date":"2021","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/34779914","citation_count":32,"is_preprint":false},{"pmid":"34883387","id":"PMC_34883387","title":"GBA mutations, glucosylceramide and Parkinson's disease.","date":"2021","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34883387","citation_count":31,"is_preprint":false},{"pmid":"36768367","id":"PMC_36768367","title":"GBA1 Gene Mutations in α-Synucleinopathies-Molecular Mechanisms Underlying Pathology and Their Clinical Significance.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36768367","citation_count":30,"is_preprint":false},{"pmid":"35262230","id":"PMC_35262230","title":"Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.","date":"2022","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/35262230","citation_count":30,"is_preprint":false},{"pmid":"29703245","id":"PMC_29703245","title":"D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.","date":"2018","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/29703245","citation_count":30,"is_preprint":false},{"pmid":"37195859","id":"PMC_37195859","title":"A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.","date":"2023","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/37195859","citation_count":29,"is_preprint":false},{"pmid":"24894157","id":"PMC_24894157","title":"The significance of GBA for Parkinson's disease.","date":"2014","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/24894157","citation_count":29,"is_preprint":false},{"pmid":"39000225","id":"PMC_39000225","title":"GBA1-Associated Parkinson's Disease Is a Distinct Entity.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39000225","citation_count":27,"is_preprint":false},{"pmid":"38027469","id":"PMC_38027469","title":"Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol.","date":"2023","source":"BMJ neurology open","url":"https://pubmed.ncbi.nlm.nih.gov/38027469","citation_count":27,"is_preprint":false},{"pmid":"36611984","id":"PMC_36611984","title":"The Consequences of GBA Deficiency in the Autophagy-Lysosome System in Parkinson's Disease Associated with GBA.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36611984","citation_count":27,"is_preprint":false},{"pmid":"31288942","id":"PMC_31288942","title":"Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?","date":"2019","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31288942","citation_count":26,"is_preprint":false},{"pmid":"23151684","id":"PMC_23151684","title":"Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.","date":"2012","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/23151684","citation_count":26,"is_preprint":false},{"pmid":"35978378","id":"PMC_35978378","title":"Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson's disease.","date":"2022","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/35978378","citation_count":26,"is_preprint":false},{"pmid":"32557794","id":"PMC_32557794","title":"Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.","date":"2020","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/32557794","citation_count":25,"is_preprint":false},{"pmid":"36130205","id":"PMC_36130205","title":"The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36130205","citation_count":25,"is_preprint":false},{"pmid":"38656622","id":"PMC_38656622","title":"GBA moderates cognitive reserve's effect on cognitive function in patients with Parkinson's disease.","date":"2024","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38656622","citation_count":25,"is_preprint":false},{"pmid":"38303548","id":"PMC_38303548","title":"The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons.","date":"2024","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/38303548","citation_count":24,"is_preprint":false},{"pmid":"26857292","id":"PMC_26857292","title":"Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.","date":"2016","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/26857292","citation_count":24,"is_preprint":false},{"pmid":"37658046","id":"PMC_37658046","title":"Mutational spectrum and clinical features of GBA1 variants in a Chinese cohort with Parkinson's disease.","date":"2023","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/37658046","citation_count":24,"is_preprint":false},{"pmid":"29846835","id":"PMC_29846835","title":"Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.","date":"2018","source":"Brain topography","url":"https://pubmed.ncbi.nlm.nih.gov/29846835","citation_count":24,"is_preprint":false},{"pmid":"33998549","id":"PMC_33998549","title":"Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers.","date":"2021","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/33998549","citation_count":23,"is_preprint":false},{"pmid":"34951095","id":"PMC_34951095","title":"Prevalence and genotype-phenotype correlations of GBA-related Parkinson disease in a large Chinese cohort.","date":"2022","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34951095","citation_count":23,"is_preprint":false},{"pmid":"32623306","id":"PMC_32623306","title":"GBA variation and susceptibility to multiple system atrophy.","date":"2020","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/32623306","citation_count":22,"is_preprint":false},{"pmid":"36916660","id":"PMC_36916660","title":"A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.","date":"2023","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/36916660","citation_count":21,"is_preprint":false},{"pmid":"38843618","id":"PMC_38843618","title":"Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease.","date":"2024","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/38843618","citation_count":20,"is_preprint":false},{"pmid":"22327140","id":"PMC_22327140","title":"Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.","date":"2012","source":"Neuro-degenerative diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22327140","citation_count":20,"is_preprint":false},{"pmid":"38454456","id":"PMC_38454456","title":"GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice.","date":"2024","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/38454456","citation_count":19,"is_preprint":false},{"pmid":"31761523","id":"PMC_31761523","title":"GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.","date":"2019","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31761523","citation_count":19,"is_preprint":false},{"pmid":"35179198","id":"PMC_35179198","title":"Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35179198","citation_count":19,"is_preprint":false},{"pmid":"37558169","id":"PMC_37558169","title":"Unraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease.","date":"2023","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/37558169","citation_count":19,"is_preprint":false},{"pmid":"31751314","id":"PMC_31751314","title":"GBA mutation promotes early mitochondrial dysfunction in 3D neurosphere models.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31751314","citation_count":19,"is_preprint":false},{"pmid":"36906614","id":"PMC_36906614","title":"Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD.","date":"2023","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/36906614","citation_count":19,"is_preprint":false},{"pmid":"28933588","id":"PMC_28933588","title":"Death by over-eating: The Gaucher disease associated gene GBA1, identified in a screen for mediators of autophagic cell death, is necessary for developmental cell death in Drosophila midgut.","date":"2017","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/28933588","citation_count":19,"is_preprint":false},{"pmid":"36084847","id":"PMC_36084847","title":"Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review.","date":"2022","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/36084847","citation_count":18,"is_preprint":false},{"pmid":"38472443","id":"PMC_38472443","title":"Role of GBA variants in Lewy body disease neuropathology.","date":"2024","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/38472443","citation_count":18,"is_preprint":false},{"pmid":"39927608","id":"PMC_39927608","title":"Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.","date":"2025","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/39927608","citation_count":17,"is_preprint":false},{"pmid":"38924406","id":"PMC_38924406","title":"The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/38924406","citation_count":17,"is_preprint":false},{"pmid":"37748026","id":"PMC_37748026","title":"Cholinergic innervation topography in GBA-associated de novo Parkinson's disease patients.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37748026","citation_count":17,"is_preprint":false},{"pmid":"30106115","id":"PMC_30106115","title":"Identification of LINC01279 as a cell cycle‑associated long non‑coding RNA in endometriosis with GBA analysis.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30106115","citation_count":17,"is_preprint":false},{"pmid":"33716938","id":"PMC_33716938","title":"Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33716938","citation_count":17,"is_preprint":false},{"pmid":"39668204","id":"PMC_39668204","title":"African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1.","date":"2024","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/39668204","citation_count":16,"is_preprint":false},{"pmid":"39570889","id":"PMC_39570889","title":"Lewy pathology formation in patient-derived GBA1 Parkinson's disease midbrain organoids.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39570889","citation_count":15,"is_preprint":false},{"pmid":"38026514","id":"PMC_38026514","title":"Unraveling Autonomic Dysfunction in GBA-Related Parkinson's Disease.","date":"2023","source":"Movement disorders clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/38026514","citation_count":15,"is_preprint":false},{"pmid":"36845659","id":"PMC_36845659","title":"Association of GBA genotype with motor and cognitive decline in Chinese Parkinson's disease patients.","date":"2023","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36845659","citation_count":15,"is_preprint":false},{"pmid":"28894968","id":"PMC_28894968","title":"Lysosomal defects in ATP13A2 and GBA associated familial Parkinson's disease.","date":"2017","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/28894968","citation_count":15,"is_preprint":false},{"pmid":"38364891","id":"PMC_38364891","title":"Heterotrimeric G protein signaling without GPCRs: The Gα-binding-and-activating (GBA) motif.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38364891","citation_count":14,"is_preprint":false},{"pmid":"33388928","id":"PMC_33388928","title":"Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.","date":"2021","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33388928","citation_count":14,"is_preprint":false},{"pmid":"36574647","id":"PMC_36574647","title":"PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36574647","citation_count":14,"is_preprint":false},{"pmid":"25957717","id":"PMC_25957717","title":"Presenting symptoms of GBA-related Parkinson's disease.","date":"2015","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/25957717","citation_count":14,"is_preprint":false},{"pmid":"31965564","id":"PMC_31965564","title":"The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers.","date":"2020","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31965564","citation_count":14,"is_preprint":false},{"pmid":"31351996","id":"PMC_31351996","title":"The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease.","date":"2019","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31351996","citation_count":14,"is_preprint":false},{"pmid":"33383316","id":"PMC_33383316","title":"Impulse control behavior in GBA-mutated parkinsonian patients.","date":"2020","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33383316","citation_count":13,"is_preprint":false},{"pmid":"35419585","id":"PMC_35419585","title":"The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models.","date":"2022","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/35419585","citation_count":13,"is_preprint":false},{"pmid":"38797393","id":"PMC_38797393","title":"Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease.","date":"2024","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/38797393","citation_count":12,"is_preprint":false},{"pmid":"38641924","id":"PMC_38641924","title":"Variant-specific effects of GBA1 mutations on dopaminergic neuron proteostasis.","date":"2024","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38641924","citation_count":11,"is_preprint":false},{"pmid":"37312046","id":"PMC_37312046","title":"GBA1 in Parkinson's disease: variant detection and pathogenicity scoring matters.","date":"2023","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37312046","citation_count":11,"is_preprint":false},{"pmid":"33176831","id":"PMC_33176831","title":"The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects.","date":"2020","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33176831","citation_count":11,"is_preprint":false},{"pmid":"36057834","id":"PMC_36057834","title":"GBA1 and The Immune System: A Potential Role in Parkinson's Disease?","date":"2022","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/36057834","citation_count":10,"is_preprint":false},{"pmid":"37921246","id":"PMC_37921246","title":"Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.","date":"2023","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/37921246","citation_count":10,"is_preprint":false},{"pmid":"35241697","id":"PMC_35241697","title":"Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers.","date":"2022","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/35241697","citation_count":10,"is_preprint":false},{"pmid":"34930372","id":"PMC_34930372","title":"Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients.","date":"2021","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34930372","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54363,"output_tokens":6135,"usd":0.127557,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15031,"output_tokens":5050,"usd":0.100703,"stage2_stop_reason":"end_turn"},"total_usd":0.22826,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"GBA1 encodes glucocerebrosidase, a lysosomal enzyme that catalyzes the hydrolysis of the glycolipid glucocerebroside to ceramide and glucose; loss-of-function mutations cause lysosomal storage of glucocerebroside in reticuloendothelial cells leading to Gaucher disease. Nearly 300 unique mutations spanning the gene have been characterized, including missense, nonsense, frameshift, splice-junction mutations, and complex alleles from recombination with the downstream pseudogene GBAP1.\",\n      \"method\": \"Mutation spectrum review with structural/functional annotation of ~300 GBA variants; recombination events with pseudogene characterized\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic function established by decades of biochemical work; comprehensive mutation-function analysis replicated across many labs\",\n      \"pmids\": [\"18338393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The N370S GBA1 mutation causes ER retention of β-glucocerebrosidase-1 protein, preventing its trafficking to the lysosome, activating ER stress and the unfolded protein response, triggering Golgi fragmentation, impairing autophagy, and causing lysosomal dysfunction with cholesterol accumulation. This results in mitochondrial damage and increased cell death in patient-derived fibroblasts.\",\n      \"method\": \"Western blot, immunofluorescence, LysoTracker, Filipin staining (cholesterol), electron microscopy, flow cytometry (apoptosis, ROS, mitochondrial membrane potential) in PD patient-derived N370S/WT fibroblasts\",\n      \"journal\": \"Movement disorders : official journal of the Movement Disorder Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in single lab using patient-derived cells; no independent replication cited\",\n      \"pmids\": [\"28779532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The L444P heterozygous GBA1 mutation triggers mitochondrial dysfunction by inhibiting two steps critical for mitophagy: mitochondrial priming and autophagy induction. Overexpression of L444P GBA impeded mitochondrial priming and autophagy induction even when endogenous lysosomal GBA activity was intact, whereas genetic depletion of GBA inhibited lysosomal clearance of autophagic cargo, suggesting dual mechanisms.\",\n      \"method\": \"GbaL444P/WT knockin mice, SH-SY5Y neuroblastoma cells with L444P GBA overexpression, GBA genetic depletion, mitochondrial markers (MitoTracker, TIMM23, TOMM20), LC3B lipidation assay, ROS measurements, postmortem PD brain tissue analysis\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (KI mice, cell overexpression, genetic KD, human tissue), single lab\",\n      \"pmids\": [\"30160596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"L444P GBA heterozygous mutation reduces GBA protein levels and enzymatic activity with concomitant α-synuclein accumulation in the midbrain. α-synuclein knockout or AAV5-mediated GBA overexpression each rescued MPTP-induced dopaminergic neuron loss and motor deficits, establishing that GBA deficiency-driven α-synuclein accumulation renders dopaminergic neurons more susceptible to mitochondrial toxin MPTP.\",\n      \"method\": \"GBA+/L444P knockin mice, SNCA-/- mice, AAV5-hGBA injection, MPTP neurotoxin treatment, immunohistochemistry, HPLC for dopamine metabolites, behavioral tests, mitochondrial morphology/functional assays, Western blot\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue with two independent approaches (KO and OE), single lab\",\n      \"pmids\": [\"29310663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"D409H GBA1 mutation markedly accelerates α-synuclein pathology in A53T α-synuclein transgenic mice: it exacerbates insoluble α-synuclein aggregate formation, glial activation, neuronal degeneration, motor abnormalities, and causes loss of dopaminergic neurons in the substantia nigra. This establishes that GBA1 enzyme activity reduction accelerates synucleinopathy progression.\",\n      \"method\": \"D409H GBA1 knockin × A53T α-synuclein transgenic double-mutant mice; survival analysis, immunohistochemistry, biochemical fractionation for insoluble α-synuclein, motor behavioral testing\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic interaction model with multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"29703245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GBA1-mutant (heterozygous) patient-derived neurons exhibit prolonged mitochondria-lysosome contacts due to defective modulation of the untethering protein TBC1D15, which mediates Rab7 GTP hydrolysis required for contact untethering. This dysregulation was caused by decreased GBA1 lysosomal enzyme activity and resulted in disrupted mitochondrial distribution and function; restoring GCase activity with a modulator or overexpressing TBC1D15 rescued these defects.\",\n      \"method\": \"Patient iPSC-derived midbrain dopaminergic neurons, live-cell imaging of mitochondria-lysosome contacts (soma, axons, dendrites), GCase activity assay, TBC1D15 rescue overexpression, GCase modulator treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human patient-derived neurons, live imaging, pharmacological and genetic rescue, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"33753743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GBA1 D409V knockin astrocytes exhibit broad lysosomal morphology and functional deficits and dramatically impaired basal and TLR4-dependent cytokine production. Both lysosomal dysfunction and inflammatory responses were normalized by LRRK2 kinase inhibition, demonstrating functional crosstalk between GBA1 and LRRK2 in astrocytes.\",\n      \"method\": \"Heterozygous and homozygous D409V GBA1 knockin mouse astrocytes; biochemical and image-based lysosomal assays, cytokine transcriptional and secretory analyses (basal and TLR4-stimulated), LRRK2 kinase inhibitor treatment\",\n      \"journal\": \"Movement disorders : official journal of the Movement Disorder Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockin model, multiple orthogonal readouts, pharmacological rescue, single lab\",\n      \"pmids\": [\"32034799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"L444P GBA1 mutation produces an altered membrane sphingolipid profile in patient fibroblasts—overall elevated sphingolipids with a shift toward shorter-chain ceramide, sphingomyelin, and hexosylceramide—that directly accelerates α-synuclein aggregation kinetics in vitro. Ambroxol treatment restored glucocerebrosidase activity, normalized sphingolipid composition, and reversed the pro-aggregation effect, establishing a mechanistic link between GCase loss-of-function, lipid dyshomeostasis, and α-synuclein aggregation.\",\n      \"method\": \"Shotgun lipidomics of L444P GBA fibroblasts; recombinant α-synuclein aggregation kinetics assay with lipid extracts; lipidomics of resulting fibrils; ambroxol pharmacological rescue\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of lipid-driven α-synuclein aggregation, lipidomics of fibrils, pharmacological rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"35362022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The E326K GBA variant does not cause significant loss of GCase protein or activity, ER retention, or ER stress (in contrast to L444P), yet still leads to increased insoluble α-synuclein aggregates. Additionally, E326K causes a significant increase in lipid droplet number under basal conditions and following oleic acid loading, indicating a distinct, lipid-dyshomeostasis mechanism for this risk variant.\",\n      \"method\": \"Homozygous and heterozygous E326K human fibroblasts; E326K and L444P SH-SY5Y overexpression lines; GCase activity/protein assays, ER stress markers, α-synuclein solubility fractionation, lipid droplet staining and quantification with/without oleic acid\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two cell systems (fibroblasts and neuroblastoma lines), multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"36130205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"N370S GBA1 mutation in cholinergic neurons reduces GCase protein and activity and cathepsin D levels, and significantly increases both tau and α-synuclein protein levels. Ambroxol, a GCase chaperone, enhanced GCase activity and reversed tau and α-synuclein accumulation, establishing that GBA1 dysfunction impairs proteostasis of both α-synuclein and tau in cholinergic neurons.\",\n      \"method\": \"Neural crest stem cell-derived cholinergic neurons from N370S/WT PD patients; GCase activity assay, Western blot for GCase/cathepsin D/tau/α-synuclein, ambroxol treatment rescue\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived neuronal model, pharmacological rescue, multiple protein targets assessed, single lab\",\n      \"pmids\": [\"35179198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Severe GBA1 mutations (L444P, D409H) increase ER stress and total ubiquitination, impair macroautophagy (L444P blocks autophagosome-lysosome fusion; N370S and D409H reduce autophagosome formation), and trigger accumulation and secretion of oligomeric α-synuclein. Mild mutation N370S specifically impairs chaperone-mediated autophagy (CMA) of monomeric α-synuclein. Thus, mild and severe GBA1 mutations cause α-synuclein accumulation through distinct proteostasis mechanisms.\",\n      \"method\": \"iPSC-derived dopaminergic neurons with N370S (mild), L444P and D409H (severe) GBA1 mutations; ER stress markers, ubiquitination assays, autophagosome formation/fusion assays, CMA activity, oligomeric α-synuclein ELISA and secretion assays\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — iPSC-derived human neurons, multiple degradation pathway readouts across three mutation variants, single lab\",\n      \"pmids\": [\"38641924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GBA1 inactivation in oligodendrocytes (Cnp1-cre × loxP-Gba1 exons 9-11 flox) induces lysosomal dysfunction and inhibits myelination in vitro, and causes in vivo demyelination, axonal degeneration, α-synuclein accumulation, astrogliosis, brain lipid dyshomeostasis and functional impairment, establishing that oligodendrocyte GCase activity is required for myelination and prevention of early neurodegenerative features.\",\n      \"method\": \"Oligodendrocyte-specific Gba1 conditional knockout mice (Cnp1-cre × loxP-Gba1); Oli-neu myelination induction model with CBE inhibitor; immunofluorescence, Western blot, lipidomics, primary oligodendrocyte culture differentiation assays\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO mouse + in vitro inhibitor model, multiple orthogonal readouts including lipidomics, single lab\",\n      \"pmids\": [\"38454456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GBA1 encodes glucocerebrosidase, and loss of its activity causes accumulation of its glycolipid substrates glucosylceramide and glucosylsphingosine. GBA mutation promotes mitochondrial accumulation and impaired clearance of depolarized mitochondria in GBA-mutant neurospheres (heterozygous and homozygous), with compensatory upregulation of TFEB and PGC1α mRNA, indicating impaired mitochondrial quality control downstream of GCase deficiency.\",\n      \"method\": \"3D neurosphere model from neural crest stem cells with heterozygous and homozygous GBA mutations; CCCP-induced mitophagy; mitochondrial content/function markers, ATP levels, TFEB and PGC1α mRNA quantification, macroautophagy flux assay\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3D neuronal model, multiple mitochondrial readouts, comparison of hetero- and homozygous lines, single lab\",\n      \"pmids\": [\"31751314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"An African ancestry-specific noncoding GBA1 risk variant (rs3115534-G) disrupts an intronic branchpoint sequence in intron 8, causing retention of a partial intron 8 in transcripts. This intron-retained isoform is not protein-coding (confirmed by N-terminal antibody staining and proteomics). CRISPR editing of rs3115534 confirmed it drives aberrant splicing. Risk variant carriers show a dose-dependent reduction in glucocerebrosidase activity, establishing that this noncoding variant reduces functional GBA1 protein through a splicing mechanism.\",\n      \"method\": \"Full-length RNA transcript sequencing in risk variant vs. non-variant carriers; N-terminal GCase antibody immunoblot; proteomics; CRISPR editing of rs3115534; glucocerebrosidase activity assay across genotypes\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — CRISPR functional validation of specific variant, RNA sequencing, proteomics, enzymatic activity, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"39668204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GBA2 (non-lysosomal β-glucosidase) enzymatic activity accounts for over 85% of total brain GBA activity in wild-type mice, and is significantly elevated in GBA1-deficient mice brains compared to heterozygotes and wild-types. Some Gaucher disease patients also show markedly elevated GBA2 activity in leukocytes, suggesting a compensatory upregulation of GBA2 in response to GBA1 deficiency.\",\n      \"method\": \"Enzymatic activity assays for GBA1 and GBA2 in brain tissue from wild-type, heterozygous, and GBA1-deficient mice; GBA2 activity assay in leukocytes from 13 Gaucher patients, 10 heterozygotes, and 19 controls\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct enzymatic assays in animal tissues and human patient leukocytes, single lab, no independent replication cited\",\n      \"pmids\": [\"23151684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GBA1 (Gba1a ortholog) was identified in a signalome-wide RNAi screen as a mediator of autophagic cell death. Knockdown of Gba1a in two independent Drosophila RNAi lines delayed developmental midgut cell death during metamorphosis, establishing that GBA1 is a conserved critical regulator of autophagy levels required for autophagic cell death.\",\n      \"method\": \"RNAi screen in human lung carcinoma cells (resveratrol-induced autophagic death); two independent Gba1a RNAi lines in Drosophila midgut; morphological analysis of midgut regression during metamorphosis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent RNAi lines in Drosophila, ortholog context, confirmed in screen + in vivo model; single lab\",\n      \"pmids\": [\"28933588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Downregulation of the transcriptional repressor SATB1 leads to derepression of miR-22-3p, which reduces GBA1 expression and causes glucocerebroside accumulation. This GluCer increase alone is sufficient to impair lysosomal and mitochondrial function, inducing a cellular senescence-like phenotype in dopaminergic neurons. The SATB1–miR-22–GBA1 regulatory axis was dysregulated in PD patients and normal aging.\",\n      \"method\": \"Human and murine neuronal lines, iPSC-derived dopaminergic neurons, and mice; SATB1 knockdown, miR-22-3p manipulation, GBA expression measurement, GluCer quantification, lysosomal/mitochondrial function assays, senescence markers\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple model systems (cell lines, iPSC neurons, mice), pathway validated step-by-step, single lab\",\n      \"pmids\": [\"38303548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In iPSC-derived midbrain organoids from GBA1-PD patients, retention of mutant glucocerebrosidase in the ER and elevated glucosylceramide levels are determinants of α-synuclein aggregation into Lewy body-like inclusions with fibrillary structure and seeding activity. Reduction of GCase activity accelerated fibrillary α-synuclein deposition. Ambroxol and GZ667161 (GCase modulators) reduced α-synuclein pathology in this model.\",\n      \"method\": \"Patient iPSC-derived midbrain organoids; ER retention immunostaining, glucosylceramide quantification, α-synuclein seeding assay (propagation to healthy organoids), ambroxol/GZ667161 pharmacological rescue\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human patient-derived 3D organoid model, seeding assay, pharmacological rescue, multiple readouts, single lab\",\n      \"pmids\": [\"39570889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PGRN (progranulin, encoded by GRN) is a modifier of GCase (GBA1): PGRN deficiency in Gba9v/9v (D409V homozygous) mice exacerbates Gaucher disease phenotypes, neuroinflammation (microgliosis, astrogliosis), impaired autophagy, and PD-like pathology. A PGRN-derived peptide (ND7) that crosses the blood-brain barrier ameliorated neuropathic Gaucher and PD pathology in Gba1-mutant mice, identifying PGRN as a functional GBA1 pathway modifier.\",\n      \"method\": \"Grn KO × Gba9v/9v double-mutant mice; neurobehavioral testing, neuropathology, neuroinflammation markers, autophagy assays; ND7 peptide BBB penetration assay, ex vivo patient fibroblast rescue, in vivo rescue in Gba9v/null and PG9V mice\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double-mutant genetic interaction in vivo + pharmacological rescue, multiple readouts, single lab\",\n      \"pmids\": [\"36574647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Long-read RNA sequencing in human brain identified currently unannotated GBA1 transcripts, including protein-coding transcripts lacking the known lysosomal targeting domain that account for almost a third of GBA1 transcription, and revealed that >50% of short-read RNA-seq reads from GBA1 also map to the pseudogene GBAP1, indicating previous expression analyses were confounded. This suggests GBA1 has nonlysosomal isoforms translated in the brain.\",\n      \"method\": \"Long-read RNA sequencing (human brain); single-nucleus RNA sequencing; proteomics to confirm translation of novel isoforms; comparison with short-read RNA-seq\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — long-read sequencing + proteomics translation confirmation, novel finding from single rigorous study; nonlysosomal function of novel isoforms not yet characterized\",\n      \"pmids\": [\"38924406\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GBA1 encodes lysosomal glucocerebrosidase (GCase), which hydrolyzes glucocerebroside to ceramide and glucose; loss-of-function mutations cause ER retention of misfolded GCase, ER stress/UPR activation, lysosomal dysfunction with glucosylceramide and glucosylsphingosine accumulation, impaired autophagy-lysosomal pathway (affecting macroautophagy, CMA, and mitophagy in variant-specific ways), and downstream α-synuclein and tau accumulation—with α-synuclein aggregation further promoted by GCase-deficiency-driven sphingolipid dyshomeostasis; additionally, GBA1 deficiency dysregulates mitochondria-lysosome contact untethering via TBC1D15/Rab7, disrupts oligodendrocyte myelination, and is regulated upstream by a SATB1–miR-22–GBA1 transcriptional axis, while a noncoding African ancestry risk variant acts by disrupting an intronic branchpoint to impair GBA1 splicing and reduce GCase activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GBA1 encodes lysosomal glucocerebrosidase (GCase), which hydrolyzes the glycolipid glucocerebroside to ceramide and glucose; loss-of-function mutations cause lysosomal storage of glucocerebroside and underlie Gaucher disease, with nearly 300 characterized variants including complex alleles arising from recombination with the GBAP1 pseudogene [#0]. Pathogenic missense alleles disrupt GCase through variant-specific routes: severe mutations such as N370S and L444P drive ER retention of misfolded enzyme, activating ER stress and the unfolded protein response, fragmenting the Golgi, and impairing autophagy and lysosomal function, with downstream mitochondrial damage and cell death [#1, #10]. Loss of GCase activity produces accumulation of its substrates glucosylceramide and glucosylsphingosine and a broader sphingolipid dyshomeostasis [#12, #7], and this lipid imbalance directly accelerates α-synuclein aggregation kinetics in vitro [#7]; the milder E326K risk variant promotes insoluble α-synuclein and lipid-droplet accumulation without measurable enzyme loss or ER stress, defining a distinct lipid-centric mechanism [#8]. GCase deficiency impairs proteostasis through mutation-specific degradation defects — severe alleles block macroautophagy and CMA differently — leading to accumulation of both α-synuclein and tau, reversible by the GCase chaperone ambroxol [#9, #10]. In patient-derived midbrain neurons and organoids, reduced GCase drives α-synuclein into Lewy-body-like fibrillar inclusions with seeding activity and accelerates dopaminergic vulnerability, with genetic or pharmacological restoration of GCase or α-synuclein removal providing rescue [#3, #17]. GCase deficiency also dysregulates mitochondrial quality control, including prolonged mitochondria–lysosome contacts via defective TBC1D15/Rab7-mediated untethering [#5, #12], impairs oligodendrocyte myelination [#11], and engages cell-type-specific crosstalk with LRRK2 in astrocytes and with progranulin as a pathway modifier [#6, #18]. GBA1 expression is controlled upstream by a SATB1–miR-22 axis [#16], and an African-ancestry noncoding variant disrupts an intronic branchpoint to cause intron retention and reduce functional GCase [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established the core biochemical identity of GBA1 as lysosomal glucocerebrosidase and catalogued the loss-of-function mutation spectrum that causes Gaucher disease, framing the gene as an enzyme whose mutations span every functional class.\",\n      \"evidence\": \"Comprehensive mutation-function review with structural annotation of ~300 variants and pseudogene recombination characterization\",\n      \"pmids\": [\"18338393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address how individual mutations differ mechanistically beyond enzyme loss\", \"Connection to neurodegeneration not yet established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed that the severe N370S allele acts not merely by reducing catalysis but by retaining misfolded enzyme in the ER, linking GBA1 mutation to ER stress, UPR, Golgi fragmentation, autophagy impairment, and mitochondrial damage.\",\n      \"evidence\": \"Multi-modal imaging, cholesterol staining, EM, and flow cytometry in N370S/WT patient fibroblasts\",\n      \"pmids\": [\"28779532\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single patient-derived cell type\", \"Does not show how ER retention couples to downstream α-synuclein pathology\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined dual mechanisms by which the L444P allele disrupts mitochondrial quality control — impeding mitophagy priming/autophagy induction independently of lysosomal activity while genetic loss blocks autophagic cargo clearance — and demonstrated that GBA-driven α-synuclein accumulation renders dopaminergic neurons vulnerable, rescued by SNCA knockout or GBA overexpression.\",\n      \"evidence\": \"L444P knockin mice, SH-SY5Y overexpression/depletion, MPTP challenge, SNCA-/- and AAV-GBA rescue, human PD tissue\",\n      \"pmids\": [\"30160596\", \"29310663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of activity-independent mitophagy block not molecularly resolved\", \"Single-lab in vivo models\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated in vivo that reduced GBA1 activity accelerates synucleinopathy progression, establishing a genetic interaction between GBA1 deficiency and α-synuclein toxicity.\",\n      \"evidence\": \"D409H GBA1 knockin × A53T α-synuclein transgenic double-mutant mice with neuropathological and behavioral readouts\",\n      \"pmids\": [\"29703245\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not isolate enzyme loss from misfolding contributions\", \"Mechanism linking GCase loss to aggregation not addressed here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected substrate accumulation (glucosylceramide, glucosylsphingosine) to impaired clearance of depolarized mitochondria with compensatory TFEB/PGC1α induction, placing mitochondrial quality control downstream of GCase deficiency.\",\n      \"evidence\": \"3D neurosphere model with hetero/homozygous GBA mutations, CCCP mitophagy, autophagy flux assays\",\n      \"pmids\": [\"31751314\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Compensatory transcriptional response not functionally validated\", \"Single model system\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed cell-type-specific GBA1 biology in astrocytes and functional crosstalk with LRRK2, showing lysosomal and inflammatory deficits normalized by LRRK2 kinase inhibition.\",\n      \"evidence\": \"D409V knockin mouse astrocytes, lysosomal assays, TLR4-stimulated cytokine analysis, LRRK2 inhibitor rescue\",\n      \"pmids\": [\"32034799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of GBA1–LRRK2 crosstalk undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified a specific organelle-contact mechanism: GCase deficiency prolongs mitochondria–lysosome contacts through defective TBC1D15-mediated Rab7 GTP hydrolysis, with rescue by GCase modulation or TBC1D15 overexpression.\",\n      \"evidence\": \"Patient iPSC-derived midbrain dopaminergic neurons, live-cell contact imaging, GCase activity assays, genetic and pharmacological rescue\",\n      \"pmids\": [\"33753743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How reduced GCase activity mechanistically impairs TBC1D15 function unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguished mechanistically divergent variants — L444P drives sphingolipid remodeling that directly accelerates α-synuclein aggregation in vitro, whereas E326K promotes insoluble α-synuclein and lipid droplets without enzyme loss or ER stress — establishing lipid dyshomeostasis as a unifying yet variant-specific driver, with ambroxol rescue for L444P.\",\n      \"evidence\": \"Shotgun lipidomics, recombinant α-synuclein aggregation kinetics, fibril lipidomics, E326K/L444P fibroblast and SH-SY5Y lines, ambroxol rescue\",\n      \"pmids\": [\"35362022\", \"36130205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal lipid species not definitively isolated\", \"E326K lipid-droplet mechanism not linked to aggregation pathway\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended GBA1 proteostasis dysfunction beyond α-synuclein to tau in cholinergic neurons, and identified progranulin (GRN) as a functional GBA1 pathway modifier amenable to peptide-based rescue.\",\n      \"evidence\": \"N370S patient-derived cholinergic neurons with ambroxol rescue; Grn KO × Gba9v/9v double-mutant mice with ND7 peptide rescue\",\n      \"pmids\": [\"35179198\", \"36574647\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking GCase to tau proteostasis undefined\", \"PGRN–GCase molecular interaction not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved that mild versus severe GBA1 mutations cause α-synuclein accumulation through distinct degradation defects — severe alleles block macroautophagy and trigger oligomer secretion, while N370S selectively impairs CMA of monomeric α-synuclein.\",\n      \"evidence\": \"iPSC-derived dopaminergic neurons across N370S, L444P, D409H variants; autophagosome formation/fusion, CMA, oligomer ELISA and secretion assays\",\n      \"pmids\": [\"38641924\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Does not establish which defect dominates in patient brain\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded GBA1 biology beyond neurons to oligodendrocytes, showing GCase activity is required for myelination and prevention of demyelination, axonal degeneration, and α-synuclein accumulation.\",\n      \"evidence\": \"Oligodendrocyte-specific Gba1 conditional knockout mice and Oli-neu CBE inhibitor model with lipidomics and differentiation assays\",\n      \"pmids\": [\"38454456\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lipid species driving myelination defect not pinpointed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined upstream transcriptional control of GBA1 via a SATB1–miR-22 axis and showed glucocerebroside accumulation alone is sufficient to induce a senescence-like phenotype in dopaminergic neurons.\",\n      \"evidence\": \"Neuronal lines, iPSC-derived dopaminergic neurons and mice; SATB1 knockdown, miR-22 manipulation, GluCer quantification, senescence markers\",\n      \"pmids\": [\"38303548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct miR-22 binding to GBA1 transcript not detailed here\", \"Relevance of senescence to PD progression unestablished\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established a noncoding splicing mechanism for an African-ancestry risk variant — rs3115534 disrupts an intron 8 branchpoint causing non-coding intron-retained transcripts and dose-dependent GCase reduction — and revealed unannotated brain GBA1 isoforms lacking the lysosomal targeting domain plus pervasive GBAP1 read confounding.\",\n      \"evidence\": \"Full-length and long-read RNA sequencing, snRNA-seq, proteomics, CRISPR editing, and GCase activity assays across genotypes in human brain and carriers\",\n      \"pmids\": [\"39668204\", \"38924406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Function of nonlysosomal GBA1 isoforms uncharacterized\", \"Whether intron-retained transcript has any cellular role unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrated in human midbrain organoids that ER retention of mutant GCase and elevated glucosylceramide are determinants of fibrillar, seeding-competent α-synuclein inclusions, with GCase modulators reducing pathology.\",\n      \"evidence\": \"GBA1-PD patient iPSC-derived midbrain organoids, ER retention staining, GluCer quantification, α-synuclein seeding/propagation assay, ambroxol/GZ667161 rescue\",\n      \"pmids\": [\"39570889\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Relative contributions of ER retention versus substrate accumulation not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown what the nonlysosomal, brain-translated GBA1 isoforms lacking the lysosomal targeting domain actually do, and how the diverse variant-specific mechanisms (ER stress, lipid dyshomeostasis, autophagy/CMA defects, organelle-contact dysregulation) are quantitatively integrated to determine neurodegenerative outcome.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional assignment for nonlysosomal isoforms\", \"No unified model weighting competing pathogenic mechanisms\", \"Substrate-of-aggregation lipid species not definitively identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 12, 14]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 8, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [1, 10, 12, 15]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 7, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 3, 4, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TBC1D15\", \"RAB7\", \"LRRK2\", \"GRN\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}